Physician profile
David D'Agate
NPI 1790784395
$69,261.49
in general payments reported to CMS, 2019-2025
23 companies · $36K in 2025
The $36K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $157 · 2020: $120 · 2021: $548 · 2022: $588 · 2023: $741 · 2024: $32K · 2025: $36K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $62K · Food and Beverage: $5,708 · Travel and Lodging: $187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $61,952.25 |
| Food and Beverage | $5,708.42 |
| Travel and Lodging | $187.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $65,100.80 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $1,420.19 | 2019-2025 | |
| Esperion Therapeutics, INC. | $716.80 | 2020-2025 | Nexletol |
| Novo Nordisk INC | $350.46 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $320.85 | 2023-2025 | Jardiance |
| Daiichi Sankyo INC. | $220.63 | 2023-2024 | Injectafer |
| Pfizer INC. | $182.37 | 2022-2025 | |
| Heartflow, INC. | $154.15 | 2023-2025 | Ffrct |
| Astrazeneca Pharmaceuticals Lp | $129.65 | 2019-2025 | Farxiga, Wainua, Andexxa |
| E.R. Squibb & Sons, L.L.C. | $96.01 | 2024-2025 | Eliquis, Camzyos |
| Abbott Laboratories | $94.46 | 2019-2024 | Cardiomems, Navitor |
| Boston Scientific Corporation | $81.07 | 2025 | Watchman Flx |
| Kiniksa Pharmaceuticals International, Plc | $78.68 | 2024 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $50.81 | 2019-2023 | Evkeeza |
| Lilly USA, LLC | $43.36 | 2025 | Mounjaro, Zepbound |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $37.15 | 2024-2025 | Verquvo |
| Kowa Pharmaceuticals America, INC. | $35.78 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $34.66 | 2022-2023 | |
| Cvrx, INC. | $33.82 | 2024 | Barostim Neo System |
| Lexicon Pharmaceuticals, INC. | $24.11 | 2024 | |
| Bridgebio Pharma, INC. | $22.29 | 2025 | Attruby |
| Janssen Pharmaceuticals, INC | $18.05 | 2024 | Xarelto |
| Philips North America LLC | $15.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David D'Agate listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.